Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AIH Aesthetic Medical International Holdings Group		$0.39	$0.29 ▼ $1.43	$15.93M	-0.21	173,623 shs	184,300 shs
BACK IMAC	$0.07 +30.1%	$0.04	$0.03 ▼ $2.30	$135K	2.07	432,624 shs	2,648 shs
BMEA Biomea Fusion	$1.81 -9.0%	$1.94	$1.29 ▼ $13.07	$74.77M	-0.23	1.15 million shs	4.50 million shs
RENB Renovaro	$0.29 -16.2%	$0.33	$0.27 ▼ $2.10	$60.09M	0.55	1.58 million shs	13.22 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AIH Aesthetic Medical International Holdings Group	0.00%	0.00%	0.00%	0.00%	-34.91%
BACK IMAC	+30.14%	+30.40%	+44.89%	+25.14%	-97.09%
BMEA Biomea Fusion	-9.05%	0.00%	+30.22%	-21.30%	-59.33%
RENB Renovaro	-16.16%	-14.26%	-6.99%	-49.53%	-81.36%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AIH Aesthetic Medical International Holdings Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BACK IMAC	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BMEA Biomea Fusion	2.6662 of 5 stars	3.6	1.0	0.0	0.0	3.2	2.5	0.6
RENB Renovaro	1.3726 of 5 stars	0.0	2.0	0.0	0.0	3.3	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AIH Aesthetic Medical International Holdings Group	0.00	N/A	N/A	N/A
BACK IMAC	0.00	N/A	N/A	N/A
BMEA Biomea Fusion	3.18	Buy	$21.40	1,082.32% Upside
RENB Renovaro	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest AIH, BACK, BMEA, and RENB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/13/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/3/2025	BMEA Biomea Fusion	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$7.00
6/2/2025	BMEA Biomea Fusion	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/15/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
5/6/2025	BMEA Biomea Fusion	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $18.00
5/6/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/2/2025	BMEA Biomea Fusion	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$11.00 ➝ $3.00
3/31/2025	BMEA Biomea Fusion	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AIH Aesthetic Medical International Holdings Group	$682.59M	0.00	N/A	4.34	$0.10 per share	0.00
BACK IMAC	$72.05K	1.88	N/A	N/A	($0.66) per share	-0.10
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	$1.42 per share	N/A
RENB Renovaro	N/A	N/A	N/A	N/A	$0.89 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AIH Aesthetic Medical International Holdings Group	-$5.29M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
BACK IMAC	-$9.42M	N/A	0.00	∞	N/A	N/A	N/A	-325.44%	8/4/2025 (Estimated)
BMEA Biomea Fusion	-$138.43M	-$3.55	N/A	N/A	N/A	N/A	-197.71%	-134.84%	7/30/2025 (Estimated)
RENB Renovaro	-$88.43M	-$0.77	N/A	∞	N/A	N/A	-60.38%	-47.04%	N/A

Latest AIH, BACK, BMEA, and RENB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/5/2025	Q1 2025	BMEA Biomea Fusion	-$0.84	-$0.80	+$0.04	-$0.80	N/A	N/A
3/31/2025	Q4 2024	BMEA Biomea Fusion	-$1.00	-$0.81	+$0.19	-$0.81	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AIH Aesthetic Medical International Holdings Group	N/A	N/A	N/A	N/A	N/A
BACK IMAC	N/A	N/A	N/A	N/A	N/A
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	N/A
RENB Renovaro	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AIH Aesthetic Medical International Holdings Group	0.93	0.27	0.23
BACK IMAC	N/A	0.08	0.08
BMEA Biomea Fusion	N/A	2.25	2.25
RENB Renovaro	N/A	0.13	0.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AIH Aesthetic Medical International Holdings Group	2.13%
BACK IMAC	5.84%
BMEA Biomea Fusion	96.72%
RENB Renovaro	71.41%

Insider Ownership

Company	Insider Ownership
AIH Aesthetic Medical International Holdings Group	55.10%
BACK IMAC	12.26%
BMEA Biomea Fusion	18.42%
RENB Renovaro	21.72%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AIH Aesthetic Medical International Holdings Group	1,286	47.79 million	21.46 million	Not Optionable
BACK IMAC	180	2.07 million	1.82 million	Not Optionable
BMEA Biomea Fusion	50	37.57 million	30.65 million	Optionable
RENB Renovaro	20	172.12 million	134.74 million	Optionable

AIH, BACK, BMEA, and RENB Headlines

Recent News About These Companies

Renovaro subsidiary secures patent for drug discovery AI

June 5, 2025 | uk.investing.com

RENB-aandeel raakt 52-weeks dieptepunt van $ 0,27 door marktuitdagingen

June 5, 2025 | nl.investing.com

RENB stock touches 52-week low at $0.27 amid market challenges

June 5, 2025 | investing.com

Renovaro Obtains a U.S. Patent for its AI-Powered Platform for Medication Discovery and Diagnostics

June 5, 2025 | msn.com

Renovaro-dochter verkrijgt patent voor AI-gestuurde medicijnontwikkeling

June 3, 2025 | nl.investing.com

Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform

June 3, 2025 | globenewswire.com

Renovaro Inc. Secures Ruling to Expedite Trial Against Predictive Oncology Over Breach of Merger Agreement

May 24, 2025 | nasdaq.com

Renovaro Inc. Accelerates 2025 Lawsuit to Force Predictive Oncology Merger

May 22, 2025 | insidermonkey.com

UPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology

May 22, 2025 | globenewswire.com

Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology

May 22, 2025 | globenewswire.com

Renovaro partners with Amsterdam UMC on cancer diagnostics

May 15, 2025 | uk.investing.com

Renovaro lanceert AI-platform voor versnelling neurologische medicijnontwikkeling

May 15, 2025 | nl.investing.com

Renovaro Inc. and Amsterdam UMC Enter Exclusive Collaboration to Develop Blood Platelet RNA Diagnostics

May 15, 2025 | nasdaq.com

Renovaro launches AI platform to advance neurology drug discovery

May 15, 2025 | investing.com

Renovaro Launches Augusta, an AI-Powered Precision Neurology Platform

May 14, 2025 | globenewswire.com

Renovaro gaat samenwerking aan met Amsterdam UMC voor kankerdiagnostiek

May 13, 2025 | nl.investing.com

Renovaro and Amsterdam University Medical Center Announce Exclusive Collaboration to Advance Blood Platelet RNA Diagnostics

May 13, 2025 | globenewswire.com

RENB-aandeel raakt 52-weeks dieptepunt van $ 0,32 door marktuitdagingen

May 1, 2025 | nl.investing.com

Renovaro BioSciences expands collaboration with Nebul

April 23, 2025 | markets.businessinsider.com

Renovaro Inc. Expands Collaboration with Nebul to Enhance Early Cancer Detection Through Advanced AI Technology

April 22, 2025 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Penny Stocks Analysts Believe Are Headed Higher
By Chris Markoch | June 4, 2025
View 3 Penny Stocks Analysts Believe Are Headed Higher
3 AI Infrastructure Stocks With Strong Growth, Not Hype
By Chris Markoch | June 26, 2025
View 3 AI Infrastructure Stocks With Strong Growth, Not Hype
Super Micro Computer Stock's Rally Backed by Strong Financials
By Gabriel Osorio-Mazilli | June 19, 2025
View Super Micro Computer Stock's Rally Backed by Strong Financials
More Than a Monetary Metal: Silver's Case for Outperformance
By Jeffrey Neal Johnson | June 22, 2025
View More Than a Monetary Metal: Silver's Case for Outperformance
ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside
By Gabriel Osorio-Mazilli | June 25, 2025
View ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside

AIH, BACK, BMEA, and RENB Company Descriptions

Aesthetic Medical International Holdings Group NASDAQ:AIH

Aesthetic Medical International Holdings Group Limited provides aesthetic medical services in the People's Republic of China and Singapore. The company offers surgical aesthetic treatments, such as eye surgery, rhinoplasty, breast augmentation, and liposuction; and non-surgical aesthetic treatments, including minimally invasive and energy-based treatments, which include laser, ultrasound, and ultraviolet light treatments. It also provides general healthcare and other aesthetic medical services, such as internal medicine, urology, gynecology, and obstetrics treatment services, as well as dentistry, dermatology, and hair loss treatment services. The company was founded in 1997 and is headquartered in Shenzhen, the People's Republic of China.

IMAC NASDAQ:BACK

$0.07 +0.02 (+30.14%)

As of 06/27/2025 03:50 PM Eastern

IMAC Holdings, Inc. owns and manages innovative medical advancements and care regeneration centers, and backspace clinics in the United States. The company's outpatient medical clinics provide regenerative, orthopedic, and minimally invasive procedures and therapies to patients with sports injuries, ligament and tendon damage, and other related soft tissue conditions, as well as back, knee, and joint pains. It also provides medical treatments, regenerative, spinal decompression, chiropractic manipulation, and physical medicine and therapy. IMAC Holdings, Inc. was founded in 2000 and is headquartered in Franklin, Tennessee.

Biomea Fusion NASDAQ:BMEA

$1.81 -0.18 (-9.05%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.86 +0.05 (+3.04%)

As of 06/27/2025 07:56 PM Eastern

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Renovaro NASDAQ:RENB

$0.29 -0.06 (-16.16%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.31 +0.02 (+5.23%)

As of 06/27/2025 07:55 PM Eastern

Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time